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Neurochemical brain imaging of treatment
response in geriatric depression
Since the renewed emphasis on the heterogeneity of geriatric depression and the impact on treat-
ment response variability over a decade ago,
1 neuroimaging methods have been increasingly
applied to understand the underlying neurobiology of treatment response variability in geriatric
depression.
2 The application of neuroimaging methods has resulted in fundamental observations
with respect to the neural circuitry and the role of the serotonin system.The observations that
some patients remain symptomatic after adequate treatment with a selective serotonin uptake
inhibitor (SSRI) and that despite remission of mood symptoms, residual cognitive and other
behavioral deficits persist, suggest that other neurochemical mechanisms may be involved.This
review will focus on neurochemical imaging research in geriatric depression that has led to an
initial understanding of the neurobiological mechanisms underlying remission of depression in
late life. Future research directions to investigate the mechanisms underlying treatment resistance
of mood and cognitive aspects of the illness will be discussed.
Geriatric depression is a clinically and neurobiologically
heterogeneous disorder.
1,2The treatment of depression
in the elderly is complicated by age-related changes in
cognition,brain structure,function,and neurochemistry
,and by comorbid medical illnesses and the contribution
of neurodegenerative and cerebrovascular disease
processes.The issue of treatment response is complex
in the elderly, as several domains of symptomatology
must be considered,including mood,reward sensitivity,
and cognitive function.These domains of symptomatol-
ogy may have different mechanistic bases.For example,
cognitive deficits persist in some patients even after
remission of mood symptoms.
3,4 Deficits in several
domains of cognition have been reported in geriatric
depression. The most consistent cognitive deficits
observed in depressed patients who do not meet thecri-
teria for early Alzheimer's disease (AD) or other
dementias are slowed speed of processing and deficits
in executive function and memory.
5-8 Given the
advances in single photon emission computed tomogra-
phy (SPECT) positron emission tomography (PET),
radiotracer chemistry,and instrumentation and method-
ology development in magnetic resonance  imaging
(MRI), functional and structural imaging methods can
be applied and integrated to understand the pathophys-
iological mechanisms underlying the different symptom
domains and differential response to treatment. The
focus of this report will be to discuss the role of PET
neuroimaging methods to: (i) identify the neural cir-
cuitry associated with depression remission;(ii) investi-
gate the role of drug occupancy in treatment response;
and (iii) elucidate the potential utility of studying inter-
actions between monoamine systems in developing 
a mechanistic basis of treatment remission across
domains of symptomatology in geriatric depression.
The functional neuroanatomy of 
treatment response
The neural circuitry of geriatric depression has been
investigated using functional MRI (fMRI),diffusion ten-
sor imaging and PET methods.
9-12 Studies of the cerebral
metabolic and blood flow effects of antidepressant inter-
ventions have been performed mainly in younger
(midlife) depressed patients (as reviewed in ref 2).The
neuroimaging data,in addition to preclinical and post-
mortem neurochemical studies,have been integrated to
develop a functional neuroanatomic model of antide-
482
Poster
Copyright © 2008 LLS SAS.  All rights reserved483
www.dialogues-cns.org
pressant effects involving increased metabolism in dor-
sal structures and decreased metabolism in ventral struc-
tures.
13 Many of the brain regions that comprise this
model have been implicated in a recent meta-analysis of
neuroimaging studies in major depression.
14The regions
that are hypoactive at rest and show a lack of activation
during negative mood states and an increase with selec-
tive serotonin reuptake inhibitor (SSRI) treatment
include the dorsal pregenual cingulate gyrus,middle and
dorsolateral prefrontal cortex,insula,and superior tem-
poral gyrus.A second network identified was a cortical-
limbic network including the medial and inferior frontal
cortex and basal ganglia,structures that were overactive
at rest and during induction of negative mood states and
reduced in activity with antidepressant treatment.The
amygdala and thalamus were also implicated in the net-
work in some studies.Other regions highlighted in the
meta-analysis were the cerebellum (which showed
increased activity at rest),posterior cingulate,and medial
temporal lobe (including the parahippocampal gyrus),all
of which show abnormal activation in mood induction
paradigms.
Studies performed in patients with late-life depression
suggest that there may be differences between the func-
tional neuroanatomic alterations in older depressed
patients compared with younger patients.
11,12,15 With
respect to “baseline”(pretreatment metabolism),studies
in geriatric depression show that glucose metabolism is
increased in the patients relative to the demographically
matched control subjects in both anterior and posterior
regions that also showed evidence of atrophic changes in
patients compared with controls.These regions included
the right superior and middle frontal gyrus,left superior
(BA 9) and inferior frontal gyrus (BA 45),left precentral
gyrus,right middle temporal gyrus (BA 22),precuneus
(bilaterally) and inferior parietal lobule (bilaterally),left
cuneus and right cerebellum (Smith et al,unpublished
data).In younger patients,many of these regions have
relatively decreased activity including the dorsolateral
prefrontal cortex,posterior cingulate,and precuneus.
13,16
Thus,differences in the “baseline”state between midlife
and geriatric depressed patients may contribute to the
differences observed between the age groups in the cere-
bral metabolic effects of treatment.
With respect to the cerebral metabolic effects of treat-
ment, a similar pattern of increases and decreases has
been observed with both total sleep deprivation and
medication (citalopram) in patients who show a signifi-
cant decrease in depressive symptoms to meet the crite-
ria for remission.
11,12 Decreases in metabolism have been
observed in right anterior cingulate gyrus (BA 24),supe-
rior and middle frontal gyrus (bilaterally) and right infe-
rior frontal gyrus, superior and middle temporal gyrus
(bilaterally) and left inferior temporal gyrus,precuneus
and posterior cingulate (bilaterally),midbrain (bilater-
ally),right pons,parahippocampal gyrus,and amygdala
(bilaterally).Increases in metabolism were observed in
the putamen (bilaterally),right thalamus (pulvinar and
medial dorsal nuclei),inferior parietal lobule (bilaterally)
occipital cortex (right cuneus and left middle and inferior
occipital gyrus) and cerebellum (bilaterally). The
decreases and increases in metabolism superimposed on
an MR rendering are shown in Figure 1.
Thus,in geriatric depression,the brain regions observed
to be hypermetabolic that show evidence of atrophic
changes include structures that comprise the “default net-
work”that has been shown to be hyperactive in the rest-
ing state in younger depressed patients and hypoactive
in patients with AD.
17,18These regions are also activated
in mood induction paradigms,attentional and memory
tasks,and during conditions of hunger and satiety,
19-21 and
may be related to the cognitive and vegetative,in addi-
tion to mood,symptoms.The cortical hypermetabolism
may be a compensatory mechanism for neurodegenera-
tive changes such as amyloid deposition or neuroinflam-
mation,or may be the result of a primary or secondary
increase in glutamate concentrations as glutamate is the
primary neurotransmitter with these cortico-cortical
pathways.
22
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Figure 1. The effects of chronic citalopram treatment on cerebral glucose
metabolism in geriatric depression. Regions of metabolic decrease
(green) and increase (red) are superimposed on an MR rendering
from a representative subject. MR, magnetic resonance484
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Serotonin transporter occupancy 
and treatment response
While studies of cerebral glucose metabolism provide
invaluable information regarding changes in neural cir-
cuitry,PET neuroreceptor radiotracers can be applied to
evaluate the neurochemical substrates of the cerebral
metabolic effects observed.The serotonin transporter is
a logical initial target,as this is the primary binding site
of the SSRIs,and the serotonin transporter is located in
cortical,striatal,and limbic regions shown to be affected
by citalopram and related to treatment response.
Neuroimaging studies of the serotonin transporter have
been performed mainly in midlife depressed patients.
Reduced serotonin transporter binding in the midbrain
(including the raphe nuclei) has been reported in midlife
depressed patients.
23 In one of the initial studies of the
effects of SSRI treatment (paroxetine and citalopram)
on serotonin transporter binding,Meyer et al
24 observed
a high degree of serotonin transporter occupancy at rel-
atively low SSRI plasma concentrations.
Serotonin transporter occupancy by citalopram has been
studied in patients with geriatric depression.
25 Seven
patients underwent studies with the selective serotonin
transporter radiotracer [11C]-DASB developed by
Wilson and colleagues.
26The patients demonstrated 70%
occupancy by citalopram in the striatum and thalamus,
which was not correlated with the change in depression
ratings over the treatment interval,in addition to citalo-
pram dose and plasma concentration.Exploratory,voxel-
wise analyses revealed that the magnitude of serotonin
transporter occupancy by citalopram was observed in
regions in which significant decreases (anterior cingulate,
middle frontal gyrus,superior and middle temporal gyrus,
precuneus) and increases (inferior parietal lobule,
cuneus) in cerebral glucose metabolism have been
observed.The [11C]-DASB images from a representative
subject are shown in Figure 2.These results indicate that
serotonin transporter occupancy in cortical regions,
which can be measured using higher-resolution PET
scanners implemented in the past decade,may be rele-
vant to the clinical and cerebral metabolic effects of
citalopram in geriatric depressed patients.
Neuroimaging of monoamine interactions
Several observations suggest that the mechanism of
action of the SSRI and an understanding of the neuro-
chemical basis of treatment response variability may
involve alterations in the ability of serotonin to modulate
other neurotransmitter systems.Firstly,both acute and
chronic citalopram treatment is associated with signifi-
cant occupancy of the serotonin transporter,the initial
target site of action (greater than 70%)
24-28 Despite signif-
icant transporter occupancy, clinical antidepressant
effects are not observed acutely, and persist in some
patients even after chronic serotonin transporter occu-
pancy.Secondly,the observation that despite remission
of mood symptoms,some patients have persistent cogni-
tive deficits (eg,executive dysfunction) and other symp-
toms (eg, sleep disturbance) suggests involvement of
other neurotransmitter systems.
28,29The modulatory role
of serotonin and the SSRIs with respect to other neuro-
transmitters including dopamine,glutamate,and acetyl-
choline has been well described.
30-33 Given the nature of
the residual symptoms in depression that may have a
substrate in the dopamine system,the inability of sero-
tonin to modulate dopamine function in such patients is
a mechanistic hypothesis that can be evaluated using
neurochemical imaging methods.
Such hypotheses involving dynamic interactions between
neurotransmitter systems can be evaluated with in vivo
imaging.The demonstration that endogenous neurotrans-
mitter concentrations and interactions between neuro-
transmitter systems could be measured in vivo by com-
bining neurotransmitter receptor binding measures with
acute pharmacologic interventions has been an impor-
tant development in neurochemical brain imaging
Figure 2. Serotonin transporter occupancy by chronic citalopram treatment:
parametric [11C]-DASB images at the level of the striatum, prior to
and following citalopram treatment for a representative subject.
25
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methodology,particularly with respect to the dopamine
system.
34-36The development and application of methods
to evaluate dopamine modulation by other neurotrans-
mitter systems is an opportunity to test alternative
hypotheses regarding pathophysiology and drug mecha-
nisms of action.Serotonin modulation of dopamine func-
tion has been a particular focus of PET dopamine (D2)
receptor studies.
36,37-39 Several human studies have
observed that a pharmacologic increase in serotonin con-
centrations produced a reduction in striatal D2 receptor
availability secondary to an increase in striatal dopamine
concentrations.As shown in Figure 3, an acute dose of
citalopram that has been shown to produce significant
effects on cerebral metabolism as well as serotonin trans-
porter occupancy also produces a decrease in striatal D2
binding of the radiotracer [11C]-raclopride, consistent
with an increase in endogenous dopamine concentra-
tions.
37 Such a paradigm could be used to evaluate the
functional integrity of serotonin/dopamine interactions
in geriatric depression as a potential mechanistic basis of
such symptoms as executive dysfunction, apathy, and
sleep disturbance.While the focus of methodology devel-
opment for imaging of dynamic neurotransmitter con-
centrations and interactions has been the dopamine sys-
tems,other potentially relevant neurotransmitter systems
such as serotonin and acetylcholine have been the focus
of methodology development as well.
40,41
Future directions
Thus far,neuroimaging methods have been applied to the
understanding of the neurobiological substrates of treat-
ment response variability,and have shown the functional
neural circuitry associated with treatment response,as well
as the role of serotonin transporter occupancy by antide-
pressant medications.Given the advances in radiotracer
chemistry and instrumentation, other neurobiological
mechanisms can be investigated in smaller brain regions
that could not be imaged reliably with PET previously.
The application of dynamic measures of monoamine
function,such as those described in the previous section,
may be more sensitive than static measures such as trans-
porter or receptor availability.Active areas of radiotracer
development which might be potentially important
include adrenergic and glucocorticoid systems,as well as
tracers that could be used to measure trophic responses.
42
There are several neuropathological processes that can
be imaged with PET, such as amyloid deposition and
neuroinflammation, that might have implications for
understanding the basis of persistent cognitive impair-
ment in geriatric depression.
43-46 Another important
approach to understanding the neurobiological basis of
treatment resistance is to investigate the mechanism of
action of somatic treatments such as electroconvulsive
therapy (ECT),transcranial magnetic stimulation (TMS),
and potentially magnetic seizure therapy (MST),that are
effective in treating patients who respond poorly to anti-
depressant medications. Both TMS and MST are also
interesting research tools that can be applied to under-
standing the function of specific neural circuits.
47
In summary, molecular brain imaging can potentially
make contributions to fundamental questions in geriatric
depression that would have significant implications for
the design of more effective treatments.Such questions
include: what is the neurobiological basis of glucose
hypermetabolism in geriatric depression;does the clini-
cal management of depression in late life have a neuro-
protective effect;what is the mechanism by which com-
bined medication and psychotherapy is more effective;
what is the mechanism of action of somatic therapies that
are effective in treatment-resistant depression? ❏
Figure 3. Serotonin modulation of striatal dopamine concentrations mea-
sured with PET and [11C]-raclopride. Parametric [11C]-raclopride
images after saline infusion (top row) and after acute citalopram
administration (40mg, IV; bottom row). Images are shown at the
level of the striatum (left) and cerebellum (right) to show regions
of specific and nonspecific binding, respectively.
37 PET, positron
emission tomography
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